fda glp-1 warning september 2025 news sends letter to Novo Nordisk over potential side effects FDA sends warning letter after

A patient on 2.4 mg of semaglutide weekly might reduce to 1.0 mg or even 0.5 mg for maintenance

Not an AI report, not a chatbot

Albert Goday has received fees for investigation projects, consulting, and postgraduate training, and has participated in clinical trials sponsored by Almirall, Ascensia, Colegio de Farmacuticos de Barcelona, Esteve, Federacin Farmacutica, Fundacin Catalana Sndrome de Down, Fundaci Gol i Gorina, Instituto de Salud Carlos III, Jansen, Lilly, Menarini, MSD, Mutuam, Novo Nordisk, Pronokal, RedGDPS, Rovi, Sanofi Aventis

2019;18(2):e12898

J Biol Chem 280 , 2878528791 (2005)

In other words, patients can rest assured that the compounded solution will have similar quality and efficacy